AUTHOR=Luo Shuang , Jiang Yu , Anfu Zheng  , Zhao Yueshui , Wu Xu , Li Mingxing , Du Fukuan , Chen Yu , Deng Shuai , Chen Meijuan , Li Wanping , Li Xiaobing , Gu Li , Sun Yuhong , Xiao Zhangang , Shen Jing 

TITLE=Targeting hypoxia-inducible factors for breast cancer therapy: A narrative review

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 13 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.1064661

DOI=10.3389/fphar.2022.1064661

ISSN=1663-9812

ABSTRACT=A complex microenvironment between breast tumors and stromal cells promotes cancer progression. Hypoxia is one of the most common conditions in the tumor microenvironment that drives tumor development. Most hypoxia environment is induced by a family of transcription factors called hypoxia-inducible factors (HIFs), which induce the expression of various genes and interact with stromal cells to help cells adapt to hypoxia. The role of HIF-1 in breast cancer progression is well established, and HIF-1 have been considered as potential therapeutic targets for breast cancer. This mini-review discusses the role and mechanisms of HIF-1 in breast cancer progression, as well as ongoing therapeutic strategies targeting HIF-1. We mainly highlight targeting HIF-1 by conventional and newly discovered drug delivery systems（DDS） and drug therapies in breast cancer microenvironment.